image credit- shutterstock
Nikon CeLL innovation (NCLi), a subsidiary of Japan-based Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc., a leading stem cell technology company in the US.
This agreement provides the Japanese biopharma industry with an end-to-end solution for development and manufacturing of human mesenchymal stem cells (MSC) and extracellular vesicle (EV) therapeutics.
Drug developers can leverage RoosterBio's technology platform to accelerate the development of their advanced therapies with NCLi, and then seamlessly transition to clinical manufacturing within NCLi's Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP)/ Good Manufacturing Practice (GMP) facility designed specifically for cell therapies.
Through this collaboration, NCLi's capabilities include cell expansion, harvest, formulation, and cryopreservation of MSC in 2D flasks and 3D bioreactor, as well as downstream processing for EV purification and drug product manufacturing. RoosterBio and NCLi have successfully completed 2D flasks and 3D bioreactor MSC and EV technology transfer activities at clinically relevant manufacturing scales.
